WHWhitney E. Hornsby

Whitney E. Hornsby

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Whitney E. Hornsby has a total of 194 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Machine learning–driven spleen imaging and genomics uncover a splenic connection to coronary artery disease

    by Meghana Kamineni, Vineet Raghu, Zhanqing Hua, Haodong Tian, Buu Truong, Ahmed Alaa, Art Schuermans, Sam Friedman, Christopher Reeder, Romit Bhattacharya, et al.

    Despite advances in managing traditional risk factors, coronary artery disease (CAD) remains the leading cause of mortality. Circulating hematopoietic cells influence risk for CAD separately from traditional risk factors, but the role of a key regulating organ, the spleen, is unknown. The understudied spleen is a representation of the hematopoietic system optimally suited for unbiased radiologic investigations toward mechanistic insights. Here, we leveraged deep learning to extract 107 splenic radiomic features from abdominal magnetic resonance imaging (MRI) scans of 42,059 UK Biobank participants and of 2745 Mass General Brigham Biobank (MGBB) participants. Of these, 10 features from UK Biobank were associated with CAD. Genome-wide association analysis of CAD-associated features identified 219 loci, including 9p21. Variants at 9p21, the strongest yet mechanistically elusive CAD locus, were associated with splenic features such as run-length nonuniformity, reflecting heterogeneity of continuous texture regions. Research MRI findings were consistent internally, but external clinical validation highlighted challenges in translating analyses of abdominal MRI scans to routine clinical practice because of variability in imaging protocols and greater clinical heterogeneity among patients. Our study, combining deep learning with genomics, presents a framework to uncover potential splenic involvement in CAD and emphasizes translational gaps between research and clinical radiomics.


  • Open Access

    A Bayesian framework for longitudinal EHR and genetic discovery

    by Sarah M. Urbut, Yi Ding, Tetsushi Nakao, Satoshi Koyama, Anika Misra, Xilin Jiang, Achyutha Harish, Leslie Gaffney, Whitney E. Hornsby, Jordan W. Smoller, et al.

    Electronic health records (EHRs) provide rich longitudinal disease histories, but existing methods for analysing these data typically treat diseases in isolation1 and rarely integrate germline genetics. Here we present ALADYNOULLI, a Bayesian generative framework that jointly models longitudinal EHR diagnoses, age and polygenic risk to recover latent time-varying disease signatures and patient-specific signature loadings; the model is formulated as a mixture of probabilities rather than a probability of a mixture2, correctly accommodating simultaneous and chronic conditions. Applied to three independent biobanks (UK Biobank3, Mass General Brigham4 and All of Us; total n > 683,000) spanning up to 52 years of follow-up and 348 diseases, the model recovers 21 replicable signatures with high cross-cohort composition preservation (median of 80%) and reveals biological subtypes within diagnostic categories (Cohen's d up to 4.25; P ≤ 1 × 10-8 for 95% of comparisons). Signatures are concordant with established disease biology: carriers of familial hypercholesterolaemia5 enrich in the cardiovascular signature; carriers of clonal haematopoiesis of indeterminate potential6 in the inflammation signature; and a rare variant burden in LDLR, TTN and BRCA2 (refs. 7,8) aligns with disease specificities. A signature-based genome-wide association study identifies 151 genome-wide significant loci including cardiovascular associations missed by single-trait analyses. An explicit likelihood enables inverse probability weighting for selection bias9 while preserving biological signal. For disease prediction, ALADYNOULLI outperforms Pooled Cohort Equation (PCE), PREVENT and Gail at 1-year and 10-year horizons; disease-level (PheCode) predictions complement code-level foundation models such as Delphi-2M (ref. 10).


  • Blood Pressure Polygenic Score Predicts Long-Term Blood Pressure Control and Treatment-Resistant Hypertension

    by So Mi Jemma Cho, Yunfeng Ruan, Hyeok-Hee Lee, Satoshi Koyama, Stephen P. Juraschek, Norrina B. Allen, Eugene Yang, John W. McEvoy, Eric A. Secemsky, Michael C. Honigberg, et al.

    BACKGROUND: Suboptimal blood pressure (BP) control remains a major cardiovascular disease risk factor. Whether genetically predicted BP independently predicts long-term BP control is unknown. We examined the associations of BP polygenic scores (PGSs) with long-term BP control and treatment-resistant hypertension. METHODS: We identified 22 456 Mass General Brigham Biobank participants with hypertension. Longitudinal BP control was defined as the percentage of time above-target systolic BP (SBP) ≥130 mm Hg or diastolic BP (DBP) ≥80 mm Hg over 5 years. Using multivariable regression, we assessed the associations of BP PGS with duration above-target BP and lifetime treatment-resistant hypertension incidence. Incremental prognostic utility of BP PGSs was assessed based on the discrimination C-index, Brier score, and net reclassification index. Validation was performed in the population-based UK Biobank cohort using the SBP/DBP ≥140/90 mm Hg threshold. RESULTS: Among 10 853 (48.3%) were female, the mean SBP/DBP (SD) at index date was 132 (18)/75 (11) mm Hg, and 4126 (18.4%) developed treatment-resistant hypertension over lifetime. In reference to the low (<20th percentile) PGS group, the high (≥80th percentile) BP PGS was associated with 8.01 (95% CI, 6.68%–9.34%) longer duration with above-target SBP and 6.19 (95% CI, 5.05%–7.33%) with high DBP. Each high SBP and DBP PGS conferred 2.36 (95% CI, 2.07–2.68) and 1.75 (95% CI, 1.55–1.99)-fold higher odds of treatment-resistant hypertension. Adding BP PGSs to traditional risk factors improved treatment-resistant hypertension prediction from C-index (95% CI), 0.74 (0.73–0.75) to 0.78 (0.77–0.79). BP PGSs consistently predicted longitudinal BP management to a comparable extent in the UK Biobank. CONCLUSIONS: Harnessing BP PGSs may inform anticipated trends in BP control to warrant vigilant monitoring and augment prioritization of intensive therapy.


  • Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial

    by Liying Xue, Romit Bhattacharya, Mesbah Uddin, Tetsushi Nakao, Roger Zou, Aniruddh Patel, Sara Haidermota, Abhishek Niroula, Victoria Viscosi, Darina Postupaka, et al.

    BACKGROUND: People with HIV (PWH) experience higher cardiovascular disease event rates not fully explained by traditional risk factors. Clonal hematopoiesis of indeterminate potential (CHIP), an emerging risk factor for cardiovascular disease in the general population, has been reported to be more prevalent in PWH. METHODS: Using high-coverage targeted CHIP sequencing in the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) cardiovascular disease prevention trial, we investigated whether CHIP increases the risk of major adverse cardiovascular events (MACE) among PWH, as well as whether HIV-associated factors were associated with greater CHIP prevalence among PWH. We analyzed whole-exome and targeted sequencing from 4490 PWH without known cardiovascular disease; 1653 (36.8%) were female, and 2039 (45.4%) were Black. MACE was defined by including cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, transient ischemic attack, peripheral artery disease, revascularization, or death from an undetermined cause. RESULTS: A total of 837 (18.6%) had CHIP driver mutations, with 385 (8.6%) at variant allele fraction ≥2% and 61 (1.4%) at variant allele fraction ≥10%. Although overall CHIP was not associated with MACE, the presence of large CHIP (variant allele fraction ≥10%) was associated with increased odds for the first occurrence of myocardial infarction or cardiac catheterization, or revascularization, despite low overall event rates. Adjustments for pitavastatin treatment did not attenuate this association. Furthermore, a larger CHIP clone size was associated with lower CD4 nadir and with increased risk of MACE. CONCLUSIONS: In PWH in the REPRIEVE trial who were low-to-moderate risk for incident cardiovascular disease, CHIP was not associated with increased prospective risk of MACE. However, a large CHIP was associated with increased risk of myocardial infarction and revascularization. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02344290.


  • Open Access

    Genome-wide association study for residualized-apolipoprotein B elucidates the role of apolipoprotein B in coronary artery disease risk

    by Selena K. Zhang, Satoshi Koyama, Tiffany R. Bellomo, Sara Haidermota, Whitney Hornsby, Michael C. Honigberg, Patrick T. Ellinor, Pradeep Natarajan

    Apolipoprotein B (apoB) has emerged as a more accurate predictor of coronary artery disease risk relative to standard lipid measurements like low-density lipoprotein cholesterol (LDL-C). Here, we sought to characterize the clinical associations and genetics underlying apoB and LDL-C discordance. We derived a residualized-apoB phenotype, defined as observed minus expected apoB for an individual given their LDL-C level, in 239,144 individuals in the UK and Mass General Brigham Biobanks. Higher residualized-apoB was independently associated with increased risk of myocardial infarction (hazard ratio = 1.30 per standard deviation change, ΔR 2 = 10%). Genome-wide association analyses identified 137 significant loci for residualized-apoB, including 16 unique genomic loci significant only in residualized-apoB in our study and 2 loci not previously described in lipid studies. Key loci implicated genes involved in lipid metabolism and cardiovascular disease (i.e. NPR2 , RORA ) and were also linked to other metabolic traits, suggesting broader metabolic relevance.

  • East and South Asian-Specific Blood Pressure Trajectories and Cardiovascular Disease

    by So Mi J. Cho, Sarah Urbut, Yunfeng Ruan, Aarushi Bhatnagar, Shriienidhie Ganesh, Whitney E. Hornsby, Romit Bhattacharya, Michael C. Honigberg, Stephen P. Juraschek, Eugene Yang, et al.

    BACKGROUND: Cardiovascular disease (CVD) risk differs across Asian subgroups, possibly due to differences in hypertension burden. We characterized lifetime blood pressure (BP) trajectories for East and South Asian individuals and compared their associations with CVD risk. METHODS: Among 148 872 UK Biobank participants with primary care utilization data, life course BP trajectories were fitted as a function of age by sex according to self-identified ethnicity. We determined associations of time-averaged young adulthood (18–39 years), middle age (40–64 years), and later life (≥65 years) systolic BP (SBP) and diastolic BP with incident atherosclerotic CVD risk. RESULTS: The predicted SBP/diastolic BP (95% CI) at age 30 years was 108 (103–114)/68 (65–71) mm Hg for East Asian and 114 (110–118)/72 (71–73) mm Hg for South Asian individuals. By age 40, South Asian individuals were projected to reach an SBP of 130.0 mm Hg, whereas East Asian individuals reached the equivalent SBP by age 49 years. Among South Asian individuals, each SD increase in young adulthood SBP was associated with a higher atherosclerotic CVD risk with an odds ratio (95% CI) of 1.41 (1.12–1.75), but not among East Asians ( P interaction =0.01). Midlife SBP was associated with peripheral artery disease among South Asian individuals (odds ratio, 2.08 [95% CI, 1.51–2.88]) and with ischemic stroke among East Asian individuals (odds ratio, 3.84 [95% CI, 1.08–5.07]). Later-life SBP was associated with myocardial infarction risk by 1.52 (1.15–1.92)-fold among South Asians and ischemic stroke by 2.50 (1.06–3.80)-fold among East Asian individuals. CONCLUSIONS: East and South Asian individuals exhibit distinct BP trajectories that age-differentially associate with incident CVD. Disaggregating Asian subgroups may inform tailored hypertension screening and management.


  • Open Access

    Dynamic Importance of Genomic and Clinical Risk for Coronary Artery Disease Over the Life Course

    by Sarah M. Urbut, So Mi Jemma Cho, Kaavya Paruchuri, Buu Truong, Sara Haidermota, Gina M. Peloso, Whitney E. Hornsby, Anthony Philippakis, Akl C. Fahed, Pradeep Natarajan

    BACKGROUND: Earlier identification of high coronary artery disease (CAD) risk individuals may enable more effective prevention strategies. However, existing 10-year risk frameworks are ineffective at earlier identification. We sought to understand how the variable importance of genomic and clinical factors across life stages may significantly improve lifelong CAD event prediction. METHODS: A longitudinal study was performed using data from 2 cohort studies: the FOS (Framingham Offspring Study) with 3588 participants aged 19 to 57 years and the UKB (UK Biobank) with 327 837 participants aged 40 years to 70 years. A total of 134 765 and 3 831 734 person-time years were observed in FOS and UKB, respectively. Hazard ratios for CAD were calculated for polygenic risk score (PRS) and clinical risk factors at each age of enrollment. The relative importance of PRS and pooled cohort equations in predicting CAD events was also evaluated by age groups. RESULTS: The importance of CAD PRS diminished over the life course, with a hazard ratio of 3.58 (95% CI, 1.39–9.19) at the age of 19 years in FOS and a hazard ratio of 1.51 (95% CI, 1.48–1.54) by the age of 70 years in UKB. Clinical risk factors exhibited similar age-dependent trends. PRS significantly outperformed pooled cohort equations in identifying subsequent CAD events in the 40- to 45-year age group, with 3.2-fold more appropriately identified events. Overall, adding PRS improved the area under the receiving operating curve of the pooled cohort equations by an average of +5.1% (95% CI, 4.9%–5.2%) across all age groups; among individuals P <0.001). CONCLUSIONS: Genomic and clinical risk factors for CAD display time-varying importance across the lifespan. The study underscores the added value of CAD PRS, particularly among individuals younger than 55 years, for enhancing early risk prediction and prevention strategies. All results are available at https://surbut.github.io/dynamicHRpaper/index.html .


  • Open Access

    Integrative Metabolomics Differentiate Coronary Artery Disease, Peripheral Artery Disease, and Venous Thromboembolism Risks

    by Jiwoo Lee, Thomas C. Gilliland, Jacqueline Dron, Satoshi Koyama, Tetsushi Nakao, Kim Lannery, Megan Wong, Gina M. Peloso, Whitney E. Hornsby, Pradeep Natarajan

    BACKGROUND: Arterial and venous cardiovascular conditions, such as coronary artery disease (CAD), peripheral artery disease (PAD), and venous thromboembolism (VTE), are genetically correlated. Interrogating underlying mechanisms may shed light on disease mechanisms. In this study, we aimed to identify (1) epidemiological and (2) causal, genetic relationships between metabolites and CAD, PAD, and VTE. METHODS: We used metabolomic data from 95 402 individuals in the UK Biobank, excluding individuals with prevalent cardiovascular disease. Cox proportional-hazards models estimated the associations of 249 metabolites with incident disease. Bidirectional 2-sample Mendelian randomization (MR) estimated the causal effects between metabolites and outcomes using genome-wide association summary statistics for metabolites (n=118 466 from the UK Biobank), CAD (n=184 305 from CARDIoGRAMplusC4D 2015), PAD (n=243 060 from the Million Veterans Project), and VTE (n=650 119 from the Million Veterans Project). Multivariable MR was performed in subsequent analyses. RESULTS: We found that 196, 115, and 74 metabolites were associated ( P <0.001) with CAD, PAD, and VTE, respectively. Further interrogation of these metabolites with MR revealed 94, 34, and 9 metabolites with potentially causal effects on CAD, PAD, and VTE, respectively. There were 21 metabolites common to CAD and PAD and 4 common to PAD and VTE. Many putatively causal metabolites included lipoprotein traits with heterogeneity across different sizes and lipid subfractions. Small VLDL (very-low-density lipoprotein) particles increased the risk for CAD while large VLDL particles decreased the risk for VTE. We identified opposing directions of CAD and PAD effects for cholesterol and triglyceride concentrations within HDLs (high-density lipoproteins). Subsequent sensitivity analyses including multivariable MR revealed several metabolites with robust, potentially causal effects of VLDL particles on CAD. CONCLUSIONS: While common vascular conditions are associated with overlapping metabolomic profiles, MR prioritized the role of specific lipoprotein species for potential pharmacological targets to maximize benefits in both arterial and venous beds.


  • Open Access

    Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial

    by Roger S. Zou, Yunfeng Ruan, Buu Truong, Romit Bhattacharya, Michael T. Lu, Júlia Karády, Rachel Bernardo, Phoebe Finneran, Whitney Hornsby, Kathleen V. Fitch, et al.

    Background: Coronary artery disease (CAD) is a leading cause of death among the 38.4 million people with HIV globally. The extent to which cardiovascular polygenic risk scores (PRSs) derived in non‐HIV populations generalize to people with HIV is not well understood. Methods and Results: PRSs for CAD (GPS Mult ) and lipid traits were calculated in a global cohort of people with HIV treated with antiretroviral therapy with low‐to‐moderate atherosclerotic cardiovascular disease risk enrolled in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV). The PRSs were associated with baseline lipid traits in 4495 genotyped participants, and with subclinical CAD in a subset of 662 who underwent coronary computed tomography angiography. Among participants who underwent coronary computed tomography angiography (mean age, 50.9 [SD, 5.8] years; 16.1% women; 41.8% African, 57.3% European, 1.1% Asian), GPS Mult was associated with plaque presence with odds ratio (OR) per SD in GPS Mult of 1.42 (95% CI, 1.20–1.68; P =3.8×10 −5 ), stenosis >50% (OR, 2.39 [95% CI, 1.48–3.85]; P =3.4×10 −4 ), and noncalcified/vulnerable plaque (OR, 1.45 [95% CI, 1.23–1.72]; P =9.6×10 −6 ). Effects were consistent in subgroups of age, sex, 10‐year atherosclerotic cardiovascular disease risk, ancestry, and CD4 count. Adding GPS Mult to established risk factors increased the C‐statistic for predicting plaque presence from 0.718 to 0.734 ( P =0.02). Furthermore, a PRS for low‐density lipoprotein cholesterol was associated with plaque presence with OR of 1.21 (95% CI, 1.01–1.44; P =0.04), and partially calcified plaque with OR of 1.21 (95% CI, 1.01–1.45; P =0.04) per SD. Conclusions: Among people with HIV treated with antiretroviral therapy without documented atherosclerotic cardiovascular disease and at low‐to‐moderate calculated risk in REPRIEVE, an externally developed CAD PRS was predictive of subclinical atherosclerosis. PRS for low‐density lipoprotein cholesterol was also associated with subclinical atherosclerosis, supporting a role for low‐density lipoprotein cholesterol in HIV‐associated CAD. Registration: URL: https://www.reprievetrial.org ; Unique identifier: NCT02344290.


  • Open Access

    Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial

    by Romit Bhattacharya, Mesbah Uddin, Aniruddh P. Patel, Abhishek Niroula, Phoebe Finneran, Rachel Bernardo, Kathleen V. Fitch, Michael T. Lu, Gerald S. Bloomfield, Carlos Malvestutto, et al.

    Clonal hematopoiesis of indeterminate potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH), but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole-exome sequencing. Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP adjusting for age, sex, and smoking status. In the studied global cohort of 4486 PWH, mean age was 49.9 (standard deviation [SD], 6.4) years; 1650 (36.8%) were female; and 3418 (76.2%) were non-White. CHIP was identified in 223 of 4486 (4.97%) and in 38 of 373 (10.2%) among those aged ≥60 years. Age (odds ratio [OR], 1.07; 95% confidence interval [CI], 1.05-1.09; P < .0001) and smoking (OR, 1.37; 95% CI, 1.14-1.66; P < .001) associated with increased odds of CHIP. Globally, participants outside of North America had lower odds of CHIP including sub-Saharan Africa (OR, 0.57; 95% CI, 0.4-0.81; P = .0019), South Asia (OR, 0.45; 95% CI, 0.23-0.80; P = .01), and Latin America/Caribbean (OR, 0.56; 95% CI, 0.34-0.87; P = .014). Hispanic/Latino ethnicity (OR, 0.38; 95% CI, 0.23-0.54; P = .002) associated with significantly lower odds of CHIP. Among HIV-specific factors, CD4 nadir <50 cells/mm3 associated with a 1.9-fold (95%CI, 1.21-3.05; P = .006) increased odds of CHIP, with the effect being significantly stronger among individuals with short duration of antiretroviral therapy (ART; OR, 4.15; 95% CI, 1.51-11.1; P = .005) (Pinteraction= .0492). Among PWH at low-to-moderate CAD risk on stable ART, smoking, CD4 nadir, North American origin, and non-Hispanic ethnicity associated with increased odds of CHIP. This trial was registered at www.ClinicalTrials.gov as NCT02344290.